LMR Partners’s iBio IBIO Stock Holding History

LMR Partners’s Portfolio IBIO Stock Details IBIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-154	Closed	-$20K	–	1256
2022 Q2	$20K	Buy	+154	New	+$23.1K	﹤0.01%	1233

Other funds holding IBIO

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Ergoteles New York $68.2M AUM 36.16% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

LMR Partners's IBIO Position: Q3 2022 in Review

LMR Partners sold out of iBio (IBIO) in Q3 2022, closing a stake of 154 shares — an estimated $20K sold.

LMR Partners first reported a position in IBIO in Q2 2022 and held it in 1 quarter. The position peaked at $20K in Q2 2022. 43 funds tracked by Wall St. Rank hold IBIO as of Q3 2022.

LMR Partners reported no remaining iBio position as of Q3 2022 after selling out during the quarter.
LMR Partners sold 154 iBio shares in Q3 2022, an estimated $20K.
LMR Partners first reported a position in iBio in Q2 2022 and held it in 1 quarter.
LMR Partners's iBio position peaked at $20K in Q2 2022.
43 funds tracked by Wall St. Rank held iBio as of Q3 2022.

Based on LMR Partners's 13F filing for Q3 2022, filed 14 Nov 2022.